SITC 2023

Date: Nov 02, 2023

 

Join us at Booth #422 during the 38th Annual Meeting & Pre-Conference Programs from November 1 to November 5, 2023 at the San Diego Convention Center.

 

SITC's Annual Meeting & Pre-Conference Programs feature cutting-edge research and timely educational sessions that serve as catalysts for advancing the field—bridging the gap between translational research, development and clinical practice.
 
SITC's 38th Annual Meeting will provide a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.
The meeting will consist of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations and ample opportunity for structured and informal discussions. In addition, the meeting will include updates on major national and international initiatives coming from academia, government and industry, as well as important society projects. The meeting will conclude with a Hot Topic Symposium to address rapidly developing key issues in the field of cancer immunotherapy.
 
 
In vitro evaluation models
Services：
 
 
In vivo evaluation models
Services：
 
 

Inquiries and Quote Requests

Request a quote now. Alternatively, you can always email animal-service@cyagen.com or call 800-921-8930 to inquire about our services or obtain a quote for your project.

 Have questions for our specialists or want more information?

Request a meeting in person at SITC 2023 to discuss your project.

Click here to book the in-person meeting!

 

Our booth will feature exciting new developments in the field of cell therapy, and our team will be on hand to answer any questions and share insights. We look forward to seeing you there!

 

Contact us for a free consultation on your CAM/CGT projects.  

 

Founded in 2006, Cyagen is a global provider of genetically modified rodent models and innovative cell and gene therapy (CGT) solutions for research and development (R&D), including: disease model development, AAV discovery, drug efficacy studies, and more. The company has established extensive cooperations with scientists and institutions in more than 100 countries, leading to the publication of over 6,300 academic articles, many of which were in the three major journals of CNS (Cell, Nature, Science). From its robust foundation in animal model development, to implementation of artificial intelligence (AI)-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug R&D with our unique offering of models, data, algorithms, and services.